Michael Scott brings to BlueRock more than 20 years of experience in the field of cardiovascular medical devices and in the stem cell therapeutics landscape. In addition to overseeing BlueRock’s Toronto operations, Dr. Scott is part of the team focused on development of a cell therapy platform for delivery of dopaminergic neurons to treat Parkinson’s disease and cardiomyocytes to treat congestive heart failure. Prior to joining BlueRock, Dr. Scott served as chief development officer & vice president of R&D at ViaCyte, a clinical stage biotechnology company focused on the treatment of type I diabetes with a stem cell-based therapy product. Before ViaCyte, Dr. Scott was responsible for surgical heart valve therapy programs driving clinical trials at Edwards Lifesciences, and was the vice president of R&D at Orqis Medical, focused on treatment of congestive heart failure. He received a Ph.D. in medical biophysics from The University of Western Ontario, and masters and bachelor’s degrees in civil engineering from the University of Waterloo.